BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26462575)

  • 1. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
    Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
    Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
    Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
    Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
    Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
    ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
    Incerti M; Tognolini M; Russo S; Pala D; Giorgio C; Hassan-Mohamed I; Noberini R; Pasquale EB; Vicini P; Piersanti S; Rivara S; Barocelli E; Mor M; Lodola A
    J Med Chem; 2013 Apr; 56(7):2936-47. PubMed ID: 23489211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
    Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
    ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
    Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
    Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor.
    Incerti M; Russo S; Callegari D; Pala D; Giorgio C; Zanotti I; Barocelli E; Vicini P; Vacondio F; Rivara S; Castelli R; Tognolini M; Lodola A
    J Med Chem; 2017 Jan; 60(2):787-796. PubMed ID: 28005388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction.
    Giorgio C; Incerti M; Corrado M; Rusnati M; Chiodelli P; Russo S; Callegari D; Ferlenghi F; Ballabeni V; Barocelli E; Lodola A; Tognolini M
    Biochem Pharmacol; 2018 Jan; 147():21-29. PubMed ID: 29129483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties.
    Incerti M; Russo S; Corrado M; Giorgio C; Ballabeni V; Chiodelli P; Rusnati M; Scalvini L; Callegari D; Castelli R; Vacondio F; Ferlenghi F; Tognolini M; Lodola A
    Eur J Med Chem; 2020 Mar; 189():112083. PubMed ID: 32000051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
    Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
    PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.
    Pala D; Castelli R; Incerti M; Russo S; Tognolini M; Giorgio C; Hassan-Mohamed I; Zanotti I; Vacondio F; Rivara S; Mor M; Lodola A
    J Chem Inf Model; 2014 Oct; 54(10):2621-6. PubMed ID: 25289483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.
    Russo S; Incerti M; Tognolini M; Castelli R; Pala D; Hassan-Mohamed I; Giorgio C; De Franco F; Gioiello A; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A
    Molecules; 2013 Oct; 18(10):13043-60. PubMed ID: 24152675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells.
    Giorgio C; Mena P; Del Rio D; Brighenti F; Barocelli E; Hassan-Mohamed I; Callegari D; Lodola A; Tognolini M
    Mol Nutr Food Res; 2015 Nov; 59(11):2155-67. PubMed ID: 26307544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
    Heinzlmeir S; Kudlinzki D; Sreeramulu S; Klaeger S; Gande SL; Linhard V; Wilhelm M; Qiao H; Helm D; Ruprecht B; Saxena K; Médard G; Schwalbe H; Kuster B
    ACS Chem Biol; 2016 Dec; 11(12):3400-3411. PubMed ID: 27768280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology.
    Madasu C; Liao Z; Parks SE; Sharma KL; Bohren KM; Ye Q; Li F; Palaniappan M; Tan Z; Yuan F; Creighton CJ; Tang S; Masand RP; Guan X; Young DW; Monsivais D; Matzuk MM
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2322934121. PubMed ID: 38701119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors.
    Lim CJ; Oh KS; Ha JD; Lee JH; Seo HW; Chae CH; Kim DG; Lee MJ; Lee BH
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4080-3. PubMed ID: 25124116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical Model of EphA2-Ephrin A1 Inhibition.
    Jedwabny W; Lodola A; Dyguda-Kazimierowicz E
    Molecules; 2018 Jul; 23(7):. PubMed ID: 29997324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of EphA2 promotes tight junction formation and impairs angiogenesis in brain endothelial cells.
    Zhou N; Zhao WD; Liu DX; Liang Y; Fang WG; Li B; Chen YH
    Microvasc Res; 2011 Sep; 82(2):113-21. PubMed ID: 21726568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis.
    Hunter SG; Zhuang G; Brantley-Sieders D; Swat W; Cowan CW; Chen J
    Mol Cell Biol; 2006 Jul; 26(13):4830-42. PubMed ID: 16782872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.